A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Spratt, M.D.
Case Western Reserve University - Seidman Comprehensive Cancer Center
Study ChairKOL profile → - William Jackson, M.D.
University of Michigan Rogel Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Cornell University
New York, New York, United States
- Weill Cornell Medicine
New York, New York, United States
- University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
- University of Texas Southwestern
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Nov 2020
- Primary completion
- 31 May 2027
- Completion
- 31 May 2029
- Last update posted
- 1 May 2026
- Registered enrollment
- 102
- Registry id
- NCT04194554
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.